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Abstract
Molecular analysis of potentially actionable mutations has become routine practice in oncological
pathology. However, testing a wide range of oncogenes and mutations can be technically challenging
because of limitations associated with tumor biopsy. Circulating tumor DNA (ctDNA) is a potential
tool for the noninvasive profiling of tumors. In this study, we developed a next-generation sequencing
(NGS)-based test for the detection of clinically relevant mutations in ctDNA and evaluated the feasi-
bility of using this ctDNA NGS-based assay as an alternative to tissue genotyping. Tissue and
matched blood samples were obtained from 72 patients with advanced nonsmall cell lung cancer
(NSCLC). NGS-based testing was performed using plasma cell-free DNA (cfDNA) samples of all 72
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patients as well as tumor DNA samples of 46 patients. Of the remaining 26 patients, tDNA was
tested by amplification refractory mutation system PCR (ARMS-PCR) because of insufficient tissue
sample or quality for NGS. Of the 46 patients who had tDNA and cfDNA NGS performed, we found
20 patients were concordant between tDNA and ctDNA alterations and 21 sample pairs were dis-
cordant because of additional alterations found in tDNA. Considering all clinically relevant alterations,
the concordance rate between tDNA and ctDNA alterations was 54.9% with a sensitivity of 53.2%
and a specificity of 75.0%. Our findings demonstrate that targeted NGS using cfDNA is a feasible
approach for rapid and accurate identification of actionable mutations in patients with advanced
NSCLC, and may provide a safe and robust alternative approach to tissue biopsy.
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1 | INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the world.1
In China, the mortality of lung cancer increased dramatically in the last
three decades.2 Targeted therapeutics have shown considerably better
clinical efficacy compared with standard therapy in patients with nonsmall
cell lung cancer (NSCLC) and an oncogenic mutation.3–6 Of these cases,
most were adenocarcinoma in which an increasing number of oncogenic
driver mutations have been discovered in recent years. In the latest ver-
sion of the National Comprehensive Cancer Network (NCCN), EGFR, ALK,
and ROS1 testing were recommended before making therapy decisions.
Additionally, emerging targeted drugs were listed for genetic alterations
including BRAF V600E, MET amplification or the exon 14 skipping muta-
tion, RET rearrangements, and HER2 mutations.7 As there is a steady
increase in the number of targeted genes through existing genotype-
selected trials, the capacity for multiplexing detection will become crucial
and even indispensable in the near future. Thus, a platform such as next-
generation sequencing (NGS) that enables the detection of multiple
tumor-specific mutations in a single assay is urgently needed.
Tissue biopsy is the gold standard for molecular testing, yet poor
quality and inadequate quantity of tissue obtained makes the test inac-
cessible to approximately 20–30% patients when tissue is obtained from
core needle biopsies.8 In contrast, liquid biopsy could address this issue
given the relative ease of blood collection that is much safer and less
stressful for the patient. Moreover, there are several other advantages of
testing circulating tumor DNA (ctDNA) over tissue biopsy: (1) rebiopsy is
not always feasible with tissue, but ctDNA is accessible during the entire
disease course; (2) identify treatment resistance by the detection of
resistant clones that could be used to guide the subsequent treatment at
disease progression and explore mechanism of novel resistance; and (3)
regarding cost effectiveness and turnaround time, liquid biopsy is faster
and can cost significantly less than tissue biopsy considering the full cost
in obtaining tissue samples and the potential extra costs caused by
biopsy complications.9 With growing evidence demonstrating the reli-
ability of ctDNA in genetic profiling, the Food and Drug Administration
(FDA) from the United States approved the Cobas EGFR Mutation Test
v2 as a companion diagnostic kit for NSCLC in June 2016.
A meta-analysis concluded that ctDNA testing showed high diagnos-
tic accuracy; however, the sensitivity varies considerably depending on
the platform and detection method.10 Further, challenges remain in using
ctDNA for liquid biopsy testing because of the inherently ultra-low con-
centration of ctDNA found in peripheral blood.11 Thus, NGS sequencing
procedures and variant calling strategies must be improved to detect low
abundancy mutations while avoiding false positive results. Previous stud-
ies have specifically focused on the detection of a single biomarker or a
few hotspot mutations such as EGFR mutations using single nucleotide
variants (SNVs) or insertion/deletions (indel). The purpose of this study
was to evaluate the detection performance of four types of variants in
ctDNA on an ion proton platform using matched tumor DNA (tDNA) and
cell-free DNA (cfDNA) from plasma of patients with advanced NSCLC.
2 | MATERIALS AND METHODS
2.1 | Ethics statement and patients
The study was approved by the Institutional Review Board of the Bei-
jing Genomics Institute. All 72 patients who participated in this study
provided written informed consent for the use of blood and lung tumor
tissue. Patients were eligible for the study if they were diagnosed with
advanced NSCLC using tissue biopsy and extra blood and tumor tissue
samples were available for NGS testing (Figure 1). Patients who
received treatment prior to resection or biopsy were excluded. Most
participating patients were highly suspected to have genetic alterna-
tions based on immunohistochemistry (IHC) results. All blood samples
were obtained during the week before surgery or biopsy collection and
were immediately processed to isolate plasma. Tissue samples were col-
lected from the primary site during surgery or biopsy. Relevant clinical
and pathological information of the subject, including smoking history
and metastatic sites, were obtained from the electronic health record.
Cell line genomic DNA was purchased from the American Type Culture
Collection (ATCC, Manassas, VA). Confirmation of cell line genomic
DNA was performed by allele-specific PCR and Sanger sequencing.
2.2 | Tumor tissue genotyping
DNA was extracted from tumor tissue using the QIAamp DNA FFPE
Tissue Kit (Qiagen, Hilden, Germany). Amplification refractory mutation
system PCR (ARMS-PCR) was used to detect EGFR and KRAS using
212 | LIU ET AL.
commercial kits from AmoyDx (Xiamen, China), and fluorescence in situ
hybridization (FISH) was used to detect ALK mutations using probes
from Abbott (Shields, IL). For 63.9% of patients (46/72) who had suffi-
cient DNA samples, tDNA NGS was performed using a previously vali-
dated targeted NGS assay.12 Hybridization-based capture from 13
introns and 436 exons in 145 cancer-related genes including actionable
recurrent rearrangements and amplifications was performed. Hybrid
capture libraries were then sequenced to a read depth [(>)3200 cover-
age] using Ion Proton Sequencers (Thermo Fisher, Waltham, MA). A
clinically validated bioinformatics pipeline named ‘Otype’ was used to
detect clinically relevant genomic alterations.12
2.3 | Plasma sample genotyping
cfDNA was extracted from 4 to 5 mL of plasma using the QIAamp Cir-
culating Nucleic Acid Kit (Qiagen) according to the manufacturer’s
instructions. The input cfDNA for the assay is 30 ng to achieve the
expected assay performance. Sequencing libraries were prepared and
hybridized to the same panel as that used for the tumor sample. The
libraries were then quantified and qualified using a 2100 Bioanalyzer
with High Sensitivity DNA 1000 Analysis Kit (Agilent, Santa Clara, CA).
Finally, libraries were amplified by emulsion PCR on the Ion OneTouch
2 Instrument and loaded onto the Ion Proton Sequencer.
We developed a new Variation Hotspot Validation Toolkit (VHVT)
for the detection of four types of actionable variants in plasma, specifi-
cally SNVs, indels, rearrangements, and copy number variations (CNVs).
First, reference sequences aimed at the hotspot mutations were
assembled, then reads were mapped to the new assembled reference
to precisely distinguish the supporting reads. Moreover, log odds (LOD)
and Poisson mathematical model were integrated to control sequencing
errors. As a result, VHVT can achieve a limitation of detection at 0.01%
with sensitivity and specificity above 95% and 99%, respectively.
Detailed information regarding this software can be found in an ASCO
Abstract we reported previously.13 Rearragements were detected using
tiled probes that allow discovery of known rearrangements. Hybrid
baits covered all potential rearranged regions and were designed based
on hotspot breakpoints that reported by COSMIC. All introns fre-
quently rearranged were contained in the panel with high density. The
assay contains 57 773 different baits in total. Of these, 2522, 472, and
2237 baits were designed to capture RET, ALK and ROS1 fusions,
respectively. For ALK rearrangement, the baits focus on intron 19, exon
19 and exon 20. For the detection of CNV, we used a Z-score and hier-
archical clustering method that have been reported previously.14,15
2.4 | Mutation validation by digital PCR
Digital PCR (dPCR) was carried out to confirm the identification of hot-
spot mutations in tDNA that were absent in plasma cfDNA via NGS.
Mutant allele frequency was measured using the QuantStudio 3D Digi-
tal PCR System (Thermo Fisher) and QuantStudio 3D Digital PCR 20K
Chip Kit v2 in accordance with the manufacturer’s instructions. Briefly,
5–10 ng of cfDNA was added to dPCR reaction mixtures containing
primers and probe. The dPCR reaction was performed with the follow-
ing conditions: 1 cycle of 968C for 10 min followed by 39 cycles of
568C for 2 min and 988C for 30 s, 1 cycle of 608C for 2 min, and 1 cycle
of 108C for 10 min. dPCR data were analyzed using QuantStudio 3D
Analysis Suite Software (Thermo Fisher).
2.5 | Statistical analysis
A normal distribution assumption for continuous variables was tested
by the Shapiro-Wilk normality test. Continuous variables were
expressed as the mean and SD, or if not normally distributed as the
interquartile range (IQR). Correlations between continuous variables
were assessed by the Spearman correlation coefficient. The relation-
ship between patient clinical characteristics and concordance status
was measured by chi-square test. Differences in two independent sam-
ples of continuous variables were evaluated by the Wilcoxon Rank
Sum test or the Kolmogorov-Smirnov test, and when comparing more
than two independent samples, the Kruskal-Wallis test was used.
Using gene mutations identified in tumor tissues as reference, we
tabulated true positives (TP), true negatives (TN), false negatives (FN),
and false positives (FP). Matched tissue and plasma samples carrying
the same mutations were classified as TP, while matched tissue and
plasma samples without somatic mutations were TN. Gene mutations
found in tissue but not in plasma samples were defined as FN, and
gene mutations found in plasma samples but not in tissue were FP.
Measures of TP, TN, FN, and FP were used to calculate sensitivity,
specificity, and concordance rate.
All statistical analyses were two sided and a P < .05 was consid-
ered statistically significant. Analyses were performed using R 3.3.
3 | RESULTS
3.1 | Patient characteristics
Tissue and matched blood samples were obtained from 72 patients
with advanced NSCLC. Demographic and clinical characteristics of the
72 patients are listed in Table 1. Forty-four (61.1%) patients were male,
and 39 (54.2%) were nonsmokers. Most patients had an
FIGURE 1 Overview of the study design for the detection of
mutations in tumor tissue and plasma samples of patients with
advanced lung cancer
LIU ET AL. | 213
adenocarcinoma histological subtype (n 5 63, 87.5%), and the remain-
ing patients (n 5 9) had a diagnosis of either a squamous cell histologi-
cal subtype (n 5 3, 4.2%) or NSCLC-not otherwise specified (n 5 6,
8.3%) (Table 1). At the time of diagnosis, 58 patients whose cancer was
staged were at either stage III (31.9%) or stage IV (48.6%).
3.2 | Assay performance assessed by cell lines
Cell lines with known variants H1975 (EGFR L858R and T790M), PC-9
(EGFR p.E746-A750del), H2228 (ALK-EML4), HCC78 (ROS1_SLC34A2),
and SNU (MET amplification) were diluted to assess the analytical sen-
sitivity and limit of detection (LOD) for the different variant types
(SNV, indel, CNV, and rearrangement). We mixed DNA from mutated
cell lines with DNA from wildtype cell lines to derive various
target allele frequencies (30%, 10%, 5%, 1%, and 0.5%). Based on the
established sequencing coverage (3800-31000), the LOD was deter-
mined using a mathematical model and then validated on DNA dilu-
tions derived from cell lines (Supporting Information Table S1). The
LOD was defined as a mutation frequency that can be successfully
detected greater than 95% chance. For SNVs and indels, we deter-
mined the analytical sensitivity as 100% at a LOD of 1%. At an allele
frequency of 0.5%, 15/16 (93.8%) SNVs and 6/6 (100%) indels were
detected. Regarding rearrangements and CNVs, we detected all muta-
tions with an allele frequency 10% (Supporting Information Table S1).
The measured allele frequency was in accordance with the expected
allele frequency. We found that the assay showed a good inter-run
reproducibility when assessed using eight samples harboring three
mutations with an allele frequency of 1% (Supporting Information
Table S2). While reads containing SNVs and short indels can be
mapped to the right position using Gatk-like programs, a program
designed for germline mutation detection and widely used for somatic
mutation detection, reads containing long indels, such as EGFR EX19
deletions are often wrongly mapped especially when there are dele-
tions near the ends of the reads. Thus, Gatk did not recognize these
reads, consequently underestimating the mutation allelic frequency,
and even missed out indels when supporting reads were rare. These
findings demonstrated that a high analytical performance was achieved
using VHVT,13 which unlike other toolkits, shows an outstanding
capacity to discriminate reads, and thus, enables the detection of
actionable EGFR EX19 deletions.
3.3 | cfDNA concentration and clinical relevance
Of the 72 plasma samples collected, the median cfDNA concentration in
plasma was 15.32 ng/mL (IQR 5 9.26 ng/mL). cfDNA concentration was
not significantly associated with metastasis status, although we observed
that cfDNA concentrations were slightly higher in patients with metasta-
sis (median concentration of 13.25 vs. 16.98 ng/mL, respectively) (Sup-
porting Information Table S3). We also found that cfDNA concentrations
were not significantly associated with gender. The median concentration
was 13.16 ng/mL in males and 16.66 ng/mL in females (P5 .063).
3.4 | Somatic mutations detected in tumor samples by
NGS
Of the 72 plasma samples obtained in our study, 46 matched tumor
samples were available for mutation detection with NGS. Other sam-
ples were either unobtainable or of an insufficient quantity or quality
after performing ARMS testing in the hospital. Of these 46 tumor DNA
samples that were successfully sequenced on the Ion Proton platform,
we achieved an average sequencing depth of 3723 (Supporting Infor-
mation Figure S1). Mutations were identified in 89% of cases (41/46)
and included SNVs, indels, CNVs, and rearrangements. We identified
16 variants in 9 genes, including EGFR mutations in 17 samples, KRAS
mutations in 9 samples, ALK fusions in 5 samples, MET copy number
gains in 3 samples, and ERBB2, NRAS, RET, BRAF, and PIK3CA muta-
tions in 1 sample each. Six samples had two variants, and one sample
had three variants. The mutation profiles of patients with matched
tumor and plasma NGS results are shown in Tables 2 and 3.
3.5 | Somatic mutations detected in plasma samples
by NGS
Seventy-two plasma DNA samples were successfully sequenced on the
Ion Proton platform. The average sequencing depth was 9383 (Sup-
porting Information Figure S2). Thirty-nine of the 72 patients had 1
potentially actionable mutation. No somatic variants were detected in
the plasma cfDNA of 33 patients. Variants were detected in 9 genes
the most prevalent of which was EGFR that was found in 28 samples
and accounting for 71.8% of samples with detected variants. Among
actionable mutations, we found that EGFR L858R mutations occurred
slightly more frequently than EGFR exon 19 deletions being found in
TABLE 1 Patient characteristics
Patients with paired samples
Characteristic
All patients
n572 (%) n5 46 (%)
Gender
Male 44 61.1 30 65.2
Female 28 38.9 16 34.8
Age (years)
Median 59 57.5
Range 40–83 39–83
Smoker
No 39 54.2 24 52.2
Ever 29 40.3 18 39.1
NA 4 5.6 4 8.7
Stage
IIIa 18 25.0 6 13.0
IIIb 5 6.9 4 10.9
IV 35 48.6 22 47.8
NA 14 19.4 14 30.4
Histology
ADC 63 87.5 40 87.0
SCC 3 4.2 2 4.3
NOS 6 8.3 4 8.7
Abbreviations: ADC, adenocarcinoma; NA, not available; NOS, not
otherwise specified; SCC, squamous cell carcinoma.
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16 and 11 samples, respectively. We found that three patients had the
EML4-ALK rearrangement, which is sensitive to the ALK tyrosine-
kinase inhibitor (TKI) crizotinib, and one patient had a RET rearrange-
ment, which is sensitive to cabozantinib. In addition, we detected KRAS
mutations in six plasma samples and BRAF V600E and EGFR L861R in
one sample each. The KRAS mutations included G12A, G12C, and
G12R, variants associated with original resistance to EGFR TKI in lung
cancer. We found no co-occurring mutations in any of the plasma sam-
ples tested.
3.6 | Concordance between tumor and plasma results
We compared clinically relevant genomic alterations for 46 patients
(68%) in our 72-patient cohort who had both tDNA and cfDNA NGS
performed (Figure 2). We found that 20 patients have concordant
tDNA and cfDNA alterations, and 5 patients have no alterations in
either tDNA or plasma cfDNA. Of these 20 concordant sample pairs,
the average allele frequency of mutations in tDNA was significantly
greater than that found in plasma cfDNA (26.9% vs. 7.4%, P < .001).
The remaining 21 sample pairs were discordant because additional
alterations were found in tDNA. We found a significant positive corre-
lation between tumor and cfDNA variant allele frequency (Spearman
r 5 0.44, P 5 .027).
Considering all clinically relevant alterations, the concordance rate
between tDNA and cfDNA alterations was 54.9% with a sensitivity of
53.2%, specificity of 75.0%, and a plasma positive predictive value of
96.2%. For tDNA and plasma cfDNA from the 19 patients with metas-
tasis, the alteration concordance rate was 65%. On the other hand, the
19 samples from primary patients had a mutation concordance of 50%.
We also studied concordance for the most frequent alterations for all
72 patients who have both tDNA (NGS or routine methods) and
cfDNA NGS results. Using tDNA as reference, we found that the
TABLE 2 Concordant mutations detected by NGS in matched tissue and plasma samples
Sample ID
Tumor
stage
cfDNA concentration
(ng/mL)
Mutation detected by
NGS in tissue (MAF)
Mutation detected
by NGS in plasma (MAF)
Sequencing
coverage in plasma
1 IV 5.5 KRAS G12C (13.9%) KRAS G12C (1.0%) 492.99
2 IV 66.1 BRAF V600E (32.1%) BRAF V600E (14.2%) 138.54
3 IV 11.6 ALK-EML4 ALK-EML4 1223.82
4 IV 10.77 ALK-EML4 ALK-EML4 1118.1
5 IV 41.58 EGFR L858R (13%) EGFR L858R (2.2%) 962.39
6 IV 9.02 EGFR L858R (2%) EGFR L858R (10.3%) 750.1
7 IV 13.42 EGFR exon 19 del (17.2%) EGFR exon 19 del (4.2%) 250.9
8 NA 21.36 EGFR exon 19 del (50.2%) EGFR exon 19 del (7.1%) 1120.9
9 IV 13.08 EGFR L858R (59.6%) EGFR L858R (1.2%) 1161.76
10 NA 18.73 EGFR exon 19 del (81%) EGFR exon 19 del (24.8%) 664.91
11 IV 15.87 RET-KIF5B RET-KIF5B 1154.5
12 IIIb 12.22 ALK-EML4 ALK-EML4 883.74
13 IV 8.88 EGFR L861R (68.6%) EGFR L861R (9.4%) 1098.38
14 IIIa 17.6 KRAS G12C (59.1%) KRAS G12C (18.8%) 1168.63
15 IIIb 8.72 KRAS G12C (48.3%) KRAS G12C (12.6%) 1007.27
16 IIIb 18.6 EGFR exon 20 ins (30.8%) EGFR exon 20 ins (3.3%) 1007.27
17 NA 7.38 EGFR exon 19 del (54.5%) EGFR exon 19 del (19.5%) 490.58
18 IV 25.65 EGFR L858R (17.7%) EGFR L858R (0.4%) 1234.05
19 NA 20.71 EGFR exon 19 del (51%) EGFR exon 19 del (5.2%) 1329.51
20 IV 18.8 EGFR exon 19 del (22.3%) EGFR exon 19 del (0.6%) 1106.13
42 IIIa 13.2 NEG NEG 1374.76
43 IIIa 4.3 NEG NEG 543.32
44 IIIa 21.2 NEG NEG 786.93
45 IIIa 8.7 NEG NEG 988.87
46 IV 12.77 NEG NEG 1087.14
Abbreviations: MAF, minor allele frequency; NA, not available; NEG, negative.
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cfDNA NGS test exhibited high specificity for the detection of EGFR
L858R (100%; 51/51), EGFR exon 19 del (100%; 55/55), KRAS G12X
(100%; 57/57), and ALK rearrangement (98.3%; 59/60). The assay had
a sensitivity of 76.2% for EGFR L858R (16/21), 58.8% for EGFR exon
19 del (10/17), 75.0% for KRAS mutations (6/8), and 50% for an ALK
rearrangement (2/4) (Table 4).
3.7 | dPCR validation
All 21 patients with discordant results were positive on tumor and neg-
ative on plasma. To exclude FN results generated by NGS in plasma
samples, of which most were SNVs and indels, dPCR was performed to
10 samples. We found one sample was positive using dPCR for EGFR
L858R with a mutant allele frequency of 0.49%. Other discordant sam-
ples were not validated by dPCR because of sample insufficiency. Fur-
ther, CNVs and rearrangements could not be validated because
methods such as quantitative PCR require a significant amount of
DNA, which is not available when using cfDNA.
4 | DISCUSSION
In this study, we evaluated NGS performance using a Beijing Genomics
Institute (BGI) lung cancer panel on the Ion Proton Platform for the
detection of gene mutations in cfDNA. To our knowledge, this is the
first study to assess the performance of the Ion Proton for the detec-
tion of four distinct types of variants in cfDNA. Our assay had an over-
all sensitivity of 53.2% when all detected mutations were considered.
Mutations in plasma samples were all identified in tumor samples,
whereas 24 mutations identified in tumor tissue samples were FN
using plasma. Among the 24 FN mutations, we found that 11 were
SNVs, 7 were EGFR exon 19 deletions, 4 were CNVs, and 2 were rear-
rangements. Further, material was available for dPCR in 10 samples.
Analysis of plasma samples with dPCR only confirmed the presence of
a mutation in one case, which was EGFR L858R with a mutant allele
frequency of 0.49%. Our findings using dPCR in NGS-negative plasma
samples revealed that the variants found in tumor were likely either
not shed into the circulation or were present at an ultra-low level that
TABLE 3 Mutation detection by NGS in tissue and plasma samples in discordant sample pairs
Sample
ID
Tumor
stage
cfDNA
concentration
(ng/mL)
Mutation detected by
NGS in tissue (MAF)
Mutation
detected by NGS
in plasma (MAF)
Sequencing
coverage in
plasma
dPCR validation
results in plasma
samples (frequency)
21 IV 20 EGFR exon 19 del (46.3%) NEG 1036.77 NEG
22 NA 12.28 EGFR L858R (28%) / MET gain EGFR L858R (1.8%) 725.75
23 NA 9.27 EGFR L858R (33%) / MET gain EGFR L858R (1.3%) 844.77
24 IIIa 8.2 MET gain NEG 906.76
25 IIIb 19.6 KRAS G12V (6.9%) NEG 1034.87 NEG
26 IV 11.66 EGFR L858R (8.7%) NEG 833.72 NEG
27 NA 12.52 NRAS Q61R (3.3%) NEG 625.67
28 NA 14.8 HER2 gain NEG 922.53
29 IV 24.44 EGFR L858R / KRAS G13V (5%/4%) EGFR L858R (18.0%) 1045.08
30 IV 11.44 EGFR exon 19 del (67.4%) NEG 1212.46 NEG
31 IV 16.99 ALK-EML4 (0%) NEG 1273.5
32 IV 7.75 EGFR exon 19 del (19.2%) NEG 1013.22 NEG
33 NA 27.17 KRAS G12C / PIK3CA H1047R /
EGFR L861Q (23.7%/28.9%/18%)
NEG 1236.44 KRAS G12C NEG
34 NA 5.67 EGFR L858R / KRAS G12A (25%/3.2%) EGFR L858R (0.1%) 784.27
35 IV 20.84 ALK-EML4 NEG 1530.25
36 NA 11.76 EGFR exon 19 del / KRAS
G12R (14.6%/1.2%)
KRAS G12R (0.2%) 1276.93
37 IV 15.46 EGFR L858R (2.1%) NEG 1008.08 NEG
38 IV 37.69 KRAS G12C (7.3%) NEG 1392.36 NEG
39 NA 11.2 EGFR exon 19 del (18.8%) NEG 829.55 NEG
40 NA 14.7 EGFR exon 19 del / EGFR L
858R (21.7%/27.3%)
NEG 863.7 EGFR L858R POS,
(0.0049)
41 NA 11.07 EGFR exon 19 del (15.6%) NEG 1114.53
Abbreviations: MAF, minor allele frequency; NA, not available; NEG, negative; POS, positive.
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was beyond our limit of detection, which was set at 1% for SNVs and
indels. Among the 21 discordant samples, we found in addition to
EGFR mutations that four samples had co-occurring mutations in tumor
tissues, yet only EGFR L858R was detected in matched plasma samples.
The two cases with co-occurrence of EGFR and KRAS mutations in
tumor tissue are rare, and NGS results were confirmed in tumor tissue
by dPCR. Furthermore, we also did not detect the four cases of MET
amplification in cfDNA that were found by NGS using tDNA. MET
amplification is associated with gefitinib resistance in patients with lung
cancer and MET targeted therapy has received preclinical and clinical
trials.16,17 Identifying MET amplification in patients with lung cancer
could aid the development of personalized medicine by identifying
those patients who will benefit from treatment with MET inhibitors.
For the failure of detecting CNV in our study, there are two potential
explanations. On the one hand, the successful detection of alteration in
cfDNA is highly depending on the proportion of tumor cell in the sam-
ple to be tested. As the actual frequency of CNV in cfDNA is unknown,
a weak signal or fragmentation of the data could cause CNV signals to
be masked by the intrinsic “background” fluctuation of the data. On the
other hand, we used a targeted NGS panel that mainly designed to test
SNVs, indels and rearrangements, while detection for CNVs was lack of
optimization. Although algorithm for plasma CNV detection using WGS
(whole genome sequencing) or WES (whole exome sequencing) have
been reported in several places;14,18–20 however, the robust detection
of amplifications is limited by the context of low ctDNA fractions, and
therefore tissue-based testing is considered to be a preferred reliable
method for the detection of CNV.9,21,22 Future efforts towards
improving CNV detection using a targeted NGS panel in plasma are still
needed.
Several studies, which have mostly focused on EGFR mutations,
have reported different sensitivities for the detection of gene muta-
tions in plasma cfDNA using different detection approaches. In one
study, the sensitivity and specificity for EGFR mutation detection using
droplet digital PCR (ddPCR) were reported to be 81.82% and 98.44%
respectively,23 whereas another study found a sensitivity of 65.7% and
a specificity of 99.8% with Scorpion ARMS using the Therascreen kit
(Qiagen),24 which is the most frequently used method. The sensitivity
of detecting EGFR mutations in plasma cfDNA using an NGS-based
approach was comparable to that found using other methods. A meta-
analysis of 27 studies using NGS reported a sensitivity and specificity
of 62.0% and 95.9%, respectively.10 In our study, we found a sensitivity
and specificity of 68.4% and 100%. However, a limitation of ddPCR
TABLE 4 Sensitivity, specificity, and concordance rate of NGS ctDNA assay
Genetic alteration n Sensitivity (%) TP FN Specificity (%) TN FP Concordance rate (%) Kappa (95% CI)
EGFR L858R 72 76.2 16 5 100 51 0 93.1 0.819 (0.669-0.969)
EGFR EXON 19 del 72 58.8 10 7 100 55 0 90.3 0.685 (0.475-0.895)
KRAS G12X 65 75.0 6 2 100 57 0 96.9 0.840 (0.625-1.000)
ALK rearrangement 64 50.0 2 2 98.3 59 1 96.9 0.547 (0.092-1.000)
Abbreviations: FN, false negative; TP, true positive.
FIGURE 2 Mutation detection by tDNA and ctDNA NGS. Patients were categorized based on histology type, stage, smoking history,
gender, and age (top). The mutation type (SNP, indel, CNV, rearrangement) identified in tDNA (middle) is compared with that found in
plasma ctDNA (bottom). Samples without mutations are shown at the far right [Color figure can be viewed at wileyonlinelibrary.com]
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and ARMs is the inherent inability to multiplex and test multiple bio-
markers simultaneously. NGS has been intensively adapted for routine
clinical use for personalized therapy.25 A major advantage of this tech-
nology is the simultaneous testing of multiple clinically actionable gene
mutations in a single assay that is both timely and cost-effective. Some
more sensitive NGS-based detection method for liquid biopsy have
been developed in recent years, but limitations exist for their wide-
spread adoption in clinical application. For instance, Cancer Personal-
ized Profiling by deep Sequencing (CAPP-SEQ), as a typical example for
hybridization based methods, is expensive due to low percentage of
reads mapping on-target. Oncomine, as an example for multiple PCR
based technique, is unable to detect DNA rearrangements. Thus, a
highly sensitive technique with affordable costs and ability to detect all
major classes of mutations is needed for abroad application of liquid
biopsy in routine clinical settings.
In the present study, 21 sample pairs were discordant with all
alterations identified in specifically tDNA. The discordance may be
due to the low concentration of ctDNA found in plasma, which
results in a lower mutation frequency in plasma cfDNA than in tis-
sue DNA. The results of dPCR partly supported this our assumption.
Among 10 cases with mutations in tDNA only, merely one plasma
was found positive using dPCR with a mutant allele frequency of
0.49%, indicating the mutations were either not shed into blood or
the concentration of the mutation is below the detection limit of
our method. In addition, our assay may not be sufficiently sensitive
to detect very low frequency alterations that may be more readily
identified by testing tissue, especially towards detection of CNVs
and gene arrangements. In our matched sample pairs, four discord-
ant samples have either a MET or HER2 CNV in tDNA, but none
was detected in the corresponding cfDNA samples (Supporting
Information Figures S3 and S4).
Previous research has shown that the proportion of ctDNA in
plasma varies by tumor size, disease stage, and the number of meta-
static sites.26,27 Similarly, our results show that M1 stage patients have
higher concordance than M0 stage patients. These results suggest that
the amount of cfDNA may reflect tumor burden and could be a bio-
marker for disease monitoring.
Clinically actionable alterations found in plasma cfDNA can also
assist in guiding the selection of targeted therapies. Actionable altera-
tions included in guidelines from the NCCN, AMP, ASCO, and CAP
were found in 39 patients with lung cancer (54.2%) in our cohort (Table
5). Furthermore, EGFR alterations (L858R and exon 19 del) were the
most frequent alterations found in cfDNA from 26 plasma samples in
our study, both of which are actionable with approved EFGR TKIs (erlo-
tinib, gefitinib, and afatinib).3,6,28 Previous studies reported that EGFR
mutations are predominantly observed in nonsquamous NSCLC, in
patients who are nonsmokers, and in Asian patients.29 In the current
study, we observed a putatively significant difference between EGFR
mutations and smoking status (P 5 .057). Additionally, drug resistance
is a major clinical problem in patients responsive to EGFR-TKIs. An
understanding of the molecular mechanisms responsible for acquired
resistance is crucial including the development of primary resistance
and the role of acquired mutations in EGFR (T790M and the exon 21
insertion) and in other oncogenes, such as BRAF, PIK3CA, HER2, and
MET.30,31 In our study, one EGFR exon 21 insertion and six KRAS acti-
vating mutations detected in cfDNA were previously associated with
either a much lower response or acquired resistance to TKIs. No other
acquired resistance mutation was found in our patient cohort. For
inclusion in our study, these patients did not receive EGFR TKI-based
therapy, which demonstrates the urgent need to provide a cfDNA test
for actionable mutations early to patients with lung cancer to ensure
they receive effective and timely personalized treatment.
In conclusion, we successfully developed a ctDNA NGS assay and
analysis pipeline that can be used to detect cancer-related mutations
and rearrangements in plasma samples obtained from patients with
advanced NSCLC. Our results showed high concordance in the detec-
tion of clinically actionable alterations found in tumor tissues and
paired plasma samples. In addition, we found that concordance rate is
associated with cancer stage and tumor aggressiveness. Our ctDNA
NGS test has great prospects for mutation profiling in patients who are
unable to provide a histological sample, and may be a less invasive,
more comprehensive, and cost-effective approach to identify targeted
therapeutic strategies and monitor treatment response in patients with
lung cancer.
TABLE 5 Genomic alterations associated with targeted therapies
Gene Geneticalteration Targeted therapy Sensitive (S) or resistant (R) Frequency (%)
All gene(s) 39
EGFR L858R Erlotinib, Gefitinib, Afatinib S 16 (41.0)
L861Q Erlotinib, Gefitinib, Afatinib S 1 (2.6)
EXON 19 DEL Erlotinib, Gefitinib, Afatinib S 11 (28.2)
EXON 20 INS Erlotinib, Gefitinib, Afatinib S 1 (2.6)
KRAS G12X Erlotinib, Gefitinib R 6 (15.4)
ALK EML4-ALK Crizotinib, Ceritinib, Alecensa S 2 (5.1)
RET RET-KIF5B Crizotinib S 1 (2.6)
BRAF V600E Vemurafenib, Dabrafenib S 1 (2.6)
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